Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 11, 2008. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary shares, filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share ownership changes and does not contain financial performance data.
Material Changes
The material change reported is the acquisition of Ordinary shares by seven individuals under the Company's Share Reward Plan ("the Plan"). The transactions occurred on June 10, 2008, at a price of £10.62 per share. The individuals involved are Mr. AP Witty, Mr. JS Heslop, Mr. SM Bicknell, Mr. EJ Gray, Mr. D Learmouth, Mr. DS Redfern, and Ms. C Thomas. Each individual acquired 11 shares via personal contribution and 11 shares via company matching contribution.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share transactions described above in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: June 10, 2008.
- Share Price: £10.62 per Ordinary share.
- Participants: Seven senior executives and directors.
- Volume: Each participant acquired a total of 22 shares (11 personal, 11 matched).
- Plan Details: Transactions were executed under the Share Reward Plan entered into on October 5, 2001.